Oncology ·
CD70-Targeted PET/CT Shows Higher Sensitivity Than PSMA Imaging in Clear-Cell RCC
A study combining a retrospective cohort of 128 patients with a prospective head-to-head study of 36 patients compared CD70- and PSMA-targeted PET/CT for renal cell carcinoma. CD70-targeted imaging had higher sensitivity for clear-cell RCC, but detection remained limited for non-clear-cell disease.
- CD70 PET/CT sensitivity was 88.7% for clear-cell RCC.
- PSMA PET/CT sensitivity was 76.1% for clear-cell RCC.
- Treatment decisions changed in 4 of 26 patients.
- Detection rates remained limited for non-clear-cell RCC.
Researchers compared [68Ga]Ga-NOTA-RCCB6, which targets CD70, with [68Ga]Ga-PSMA-11 PET/CT in renal cell carcinoma (RCC). The retrospective cohort included 128 patients with pathologically confirmed RCC who had undergone one of the imaging tests. A separate prospective study enrolled 36 patients with suspected RCC, who underwent both scans. Outcomes included lesion sensitivity, detection rates, tracer uptake and target-to-background ratios, as well as reported effects on treatment decisions.
For clear-cell RCC, CD70-targeted imaging had higher sensitivity than PSMA-targeted imaging (88.7% vs. 76.1%; P<0.001), particularly for pulmonary and hepatic metastases. CD70-targeted imaging also showed higher uptake and target-to-background ratios at primary lesions and in pulmonary metastases. Detection rates for non-clear-cell RCC were 68.8% with CD70 targeting and 63.0% with PSMA targeting. In 9 of 26 patients, CD70 imaging expanded the extent of lesion detection; treatment decisions were affected in 4 of 26.
The findings support further evaluation of CD70-targeted PET/CT as a complement to existing imaging for clear-cell RCC. The prospective comparison was small, and the reported treatment-decision effect involved only 26 patients; the abstract does not establish whether the imaging changes improved clinical outcomes.
In practice
For patients being evaluated for clear-cell renal cell carcinoma, the study suggests CD70-targeted [68Ga]Ga-NOTA-RCCB6 PET/CT may detect more lesions than PSMA-targeted [68Ga]Ga-PSMA-11 PET/CT, particularly in the lungs and liver. This evidence does not establish that the scan should replace current imaging or improve patient outcomes. The prospective head-to-head study enrolled 36 patients, and treatment decisions were affected in 4 of 26 patients assessed for that outcome; detection was also limited for non-clear-cell RCC.
AI-generated clinical interpretation · Not editor-reviewed
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
Clinical Cancer Research: Comparison of PSMA- and CD70-targeted PET/CT in The Diagnosis of Renal Cell Carcinoma: A Retrospective Cohort and Prospective Head-to-head Study ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.